Patent · US Active

Henipavirus vaccine

US11524066B2 · kind B2 · utility

7Cited by

3References

19Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Edith JASNY · Stuttgart, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Dec 22, 2017
Grant date	Dec 13, 2022
Priority date	—
Expiry date	Oct 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18271
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.